FDA approves Trizivir November 15, 2000. Trizivir is a combination
of AZT (300 mg), 3TC (150 mg), and ABC (300 mg). The recommended
regimen is one tablet bid. This is the simplest antiretroviral regimen
available now and for the foreseeable future. The package insert
warns that "there are limited data on the use of this triple combination
regimen in patients with higher viral load levels (>100,000 copies/mL)
at baseline."
posted 11/17/2000